Revenues - Schedule of Disaggregation of Revenue (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Disaggregation of Revenue [Line Items]
Total revenues	$ 4,068,950	$ 3,834,204	$ 3,659,374
United States
Disaggregation of Revenue [Line Items]
Total revenues	3,660,109	3,489,977	3,370,379
Europe
Disaggregation of Revenue [Line Items]
Total revenues	312,706	269,243	239,638
All other
Disaggregation of Revenue [Line Items]
Total revenues	96,135	74,984	49,357
Product sales, net
Disaggregation of Revenue [Line Items]
Total revenues	3,821,164	3,736,943	3,641,429
Total Neuroscience
Disaggregation of Revenue [Line Items]
Total revenues	2,698,318	2,707,843	2,760,945
Xywav
Disaggregation of Revenue [Line Items]
Total revenues	1,473,202	1,272,977	958,425
Xyrem
Disaggregation of Revenue [Line Items]
Total revenues	233,816	569,730	1,020,453
Epidiolex/Epidyolex
Disaggregation of Revenue [Line Items]
Total revenues	972,423	845,468	736,398
Sativex
Disaggregation of Revenue [Line Items]
Total revenues	18,877	19,668	16,825
Sunosi
Disaggregation of Revenue [Line Items]
Total revenues	0	0	28,844
Total Oncology
Disaggregation of Revenue [Line Items]
Total revenues	1,111,375	1,015,254	873,841
Rylaze/Enrylaze
Disaggregation of Revenue [Line Items]
Total revenues	410,846	394,226	281,659
Zepzelca
Disaggregation of Revenue [Line Items]
Total revenues	320,318	289,533	269,912
Defitelio/defibrotide
Disaggregation of Revenue [Line Items]
Total revenues	216,565	184,000	194,290
Vyxeos
Disaggregation of Revenue [Line Items]
Total revenues	162,595	147,495	127,980
Ziihera
Disaggregation of Revenue [Line Items]
Total revenues	1,051	0	0
Other
Disaggregation of Revenue [Line Items]
Total revenues	11,471	13,846	6,643
High-sodium oxybate AG royalty revenue
Disaggregation of Revenue [Line Items]
Total revenues	217,575	75,918	0
Other royalty and contract revenues
Disaggregation of Revenue [Line Items]
Total revenues	$ 30,211	$ 21,343	$ 17,945